Brief: Medivir Gets European Patent For Fostrox Plus Lenvatinib
19/03/2025 08:17
March 19 (Reuters) - Medivir AB MEDIVIR.ST: MEDIVIR RECEIVES EUROPEAN PATENT FOR FOSTROX PLUS LENVATINIB IN TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC) AND CANCER METASTASES IN THE LIVER PATENT PROVIDES PROTECTION AND MARKET EXCLUSIVITY UNTIL APRIL 2041 Source text: ID:nMFN2J3sDJ Further company coverage: MEDIVIR.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))